Maverick Capital’s Editas Medicine EDIT Stock Holding History

Maverick Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-331	Closed	-$14K	–	721
2021 Q1	$14K	Buy	+331	New	+$18.9K	﹤0.01%	681

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Maverick Capital's EDIT Position: Q2 2021 in Review

Maverick Capital sold out of Editas Medicine (EDIT) in Q2 2021, closing a stake of 331 shares — an estimated $14K sold.

Maverick Capital first reported a position in EDIT in Q1 2021 and held it in 1 quarter. The position peaked at $14K in Q1 2021. 313 funds tracked by Wall St. Rank hold EDIT as of Q2 2021.

Maverick Capital reported no remaining Editas Medicine position as of Q2 2021 after selling out during the quarter.
Maverick Capital sold 331 Editas Medicine shares in Q2 2021, an estimated $14K.
Maverick Capital first reported a position in Editas Medicine in Q1 2021 and held it in 1 quarter.
Maverick Capital's Editas Medicine position peaked at $14K in Q1 2021.
313 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2021.

Based on Maverick Capital's 13F filing for Q2 2021, filed 16 Aug 2021.